The cytotoxicity of three patient‐derived CAR T cells against autologous primary B cells confirms our hypothesis that BAFF‐R CAR T cells treatment holds a promise as an effective therapy for CLL patients. The gene discussed is TNFRSF13C; the disease is B-cell chronic lymphocytic leukemia.